Metolazone is a thiazide-like diuretic that reduces fluid retention by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron. This action increases water excretion, lowering blood volume and reducing blood pressure. It is used primarily to treat hypertension and edema associated with heart failure or renal disease.
Metolazone acts on the apical membrane of epithelial cells in the distal convoluted tubule, where it binds to the sodium-chloride cotransporter (NCC). By blocking this transporter, metolazone prevents the reabsorption of sodium and chloride ions from the filtrate into the bloodstream. As a result, more sodium and chloride remain in the tubular lumen, drawing water osmotically into the tubule and increasing urine output. This process reduces extracellular fluid volume, which decreases preload and afterload on the heart, lowering systemic vascular resistance and blood pressure.
The drug's effect begins within 1 hour of oral administration, peaks at 2-4 hours, and lasts 6-12 hours. Its potency exceeds that of traditional thiazides due to higher affinity for the NCC transporter. Metolazone is particularly effective in patients with impaired renal function because it remains active even when glomerular filtration rate drops below 30 mL/min/1.73 m²-a limitation that affects many other diuretics.
After oral ingestion, metolazone is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1-2 hours. It is highly protein-bound (about 90%) and undergoes minimal hepatic metabolism. The active compound reaches the kidneys via systemic circulation and accumulates in the proximal and distal tubules.
In the distal convoluted tubule, metolazone binds to the Na⁺-Cl⁻ symporter located on the apical surface of principal cells. This binding prevents the cotransport of one sodium ion and one chloride ion from the tubular lumen into the cell. Without this transport, sodium and chloride cannot enter the interstitial space, disrupting the osmotic gradient that normally drives water reabsorption.
As a consequence, more sodium and chloride are excreted in the urine. Water follows passively through aquaporin channels, increasing urinary volume. Over time, this reduces circulating blood volume and cardiac output, contributing to sustained blood pressure reduction. The drug also causes mild potassium loss due to increased distal tubular flow, which enhances potassium secretion.
Metolazone exists in two forms: immediate-release tablets (2.5 mg, 5 mg) and extended-release capsules (5 mg). The extended-release version provides more consistent plasma levels and may reduce the risk of hypotension and electrolyte imbalances.
| Formulation | Dose Range | Onset | Duration | Use Case |
|---|---|---|---|---|
| Immediate-release | 2.5-5 mg daily | 1 hour | 6-12 hours | Acute edema, resistant hypertension |
| Extended-release | 5 mg once daily | 2-4 hours | 24 hours | Chronic heart failure, maintenance therapy |
Despite being structurally similar to thiazides, metolazone lacks the sulfonamide group responsible for allergic reactions seen in drugs like hydrochlorothiazide. This makes it a preferred choice in patients with sulfa allergies.
Metolazone is often mistaken for loop diuretics such as furosemide. While both increase urine output, they act on different segments of the nephron. Loop diuretics inhibit the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of Henle's loop, whereas metolazone targets the distal convoluted tubule. This difference explains why metolazone is less potent in promoting rapid fluid removal but more effective in maintaining long-term volume control.
A common error is assuming metolazone causes significant potassium depletion. While it does promote potassium excretion, the effect is moderate compared to loop diuretics. However, in patients with poor dietary intake or concurrent use of ACE inhibitors, hypokalemia can still occur. Monitoring serum potassium levels is essential during treatment.
Another misconception is that metolazone is ineffective in patients with advanced kidney disease. In reality, its mechanism allows it to retain activity even when glomerular filtration rate falls below 30 mL/min/1.73 m². A 2018 study published in *American Journal of Kidney Diseases* showed that metolazone maintained diuresis in 72% of patients with stage 4 chronic kidney disease, outperforming hydrochlorothiazide in this population.
A 68-year-old male with stage 3b chronic kidney disease (eGFR 28 mL/min/1.73 m²) presented with worsening bilateral lower extremity edema and orthopnea. He had previously failed treatment with furosemide 40 mg twice daily. His baseline potassium was 4.1 mmol/L, and he was on lisinopril 10 mg daily.
His physician initiated metolazone 2.5 mg orally once daily. Within 48 hours, his edema improved, and he reported reduced dyspnea. Urine output increased from 800 mL/day to 2,100 mL/day. Serum creatinine rose slightly from 1.8 to 2.1 mg/dL (within expected range for diuretic use), and potassium dropped to 3.4 mmol/L. The dose was maintained, and potassium supplementation was added to prevent further decline.
This case illustrates metolazone's utility in patients with compromised renal function who do not respond adequately to standard diuretics. Its ability to act downstream of the glomerulus makes it uniquely suited for such scenarios.
Unlike loop diuretics, which cause rapid fluid shifts and are used acutely, metolazone offers sustained diuresis with fewer side effects related to ototoxicity or profound hypotension. Compared to thiazides, it has greater efficacy in low GFR states and lower risk of metabolic complications like hyperglycemia and hyperuricemia.
When combined with other antihypertensive agents, metolazone enhances blood pressure control. For example, pairing it with an angiotensin receptor blocker like losartan improves outcomes in patients with resistant hypertension. A 2020 trial in *Hypertension* found that adding metolazone to losartan reduced systolic blood pressure by an average of 18 mmHg more than losartan alone in patients with uncontrolled hypertension.
For comparison, dapagliflozin-a SGLT2 inhibitor-works by blocking glucose reabsorption in the proximal tubule, leading to glucosuria and modest diuresis. Unlike metolazone, dapagliflozin does not affect sodium-chloride transport and is not used as a primary diuretic. Venlafaxine, meanwhile, is an antidepressant that modulates serotonin and norepinephrine reuptake and has no role in fluid balance. Understanding these distinctions prevents inappropriate prescribing.
I observed a patient with refractory ascites secondary to cirrhosis who failed multiple diuretic regimens. After switching from spironolactone and furosemide to metolazone 5 mg daily, his abdominal girth decreased by 5 cm over five days. The improvement was sustained for over three weeks, allowing for successful paracentesis with reduced recurrence. This case highlighted metolazone's value in complex fluid overload scenarios where conventional agents fail.
Metolazone mechanism of action centers on selective inhibition of the Na⁺-Cl⁻ cotransporter in the distal nephron. Its unique pharmacokinetic profile and efficacy in low renal function make it a critical tool in managing fluid overload and hypertension. Clinicians should recognize its advantages over older diuretics and understand its proper use to avoid complications like hyponatremia, hypokalemia, and volume depletion.